Study of LX3305 and Methotrexate in Subjects With Stable Rheumatoid Arthritis

Inclusion criteria

• Males and females ≥ 18 years old
• Must be willing to practice 2 adequate methods of contraception for the duration of the study
• Rheumatoid arthritis present for at least 3 months; functional class I, II, or III as defined by ACR criteria
• Treatment with methotrexate (7.5 to 25 mg per week) for at least the last 3 months, and currently receiving stable dose methotrexate for at least one month prior to the start of the study
• Ability to provide written informed consent

Exclusion criteria

• Women who are pregnant or nursing
• History of other current inflammatory arthritis
• History of opportunistic infection
• History of recurrent infections or current infection 2 weeks prior to start of study
• Presence of significant, uncontrolled medical problems
• Treatment with any disease-modifying anti-rheumatoid drugs other than methotrexate within 4 weeks prior to start of study
• Use of chondroitin sulfate, glucosamine sulfate, minocycline, or matrix metalloproteinase inhibitors, H-2 blockers, proton pump inhibitors, or misoprostol within 4 weeks prior to study start
• Receipt of live vaccine within 8 weeks prior to study start
• Rheumatoid arthritis, functional class IV as defined by ACR criteria